 |
|
COMMENTS AND OPINIONS
HIV Eosinophilic Folliculitis in Uganda—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
Dr Colebunders and colleagues suggest that HAART alone might be as efficient as HAART and 0.1% tacrolimus therapy in controlling HIV-EF. In our experience, based on 15 cases to date, we have consistently observed accelerated improvement when we have used the combination of HAART and 0.1% tacrolimus compared with HAART alone.1
Highly active antiretroviral therapy may control HIV-EF, but it requires a fairly long time to do so, as noted by Colebunders and colleagues. This prolonged persistence of HIV-EF with HAART can be explained by the suboptimal control of HIV viremia as well as by an immune restoration syndrome. This lag can last several months, during which the patient endures a dermatosis with intense pruritus as well as disfiguring facial lesions. These symptoms may severely affect quality of life and sometimes lead to the patients' experiencing a greater difficulty in accepting and continuing HAART. We would like to . . . [Full Text of this Article]
AUTHOR INFORMATION
Laurence Toutous-Trellu, MD;
Vincent Piguet, MD, PhD
RELATED ARTICLES
HIV Eosinophilic Folliculitis in Uganda
Robert Colebunders, Barbara Castelnuovo, and Helen Byakwaga
Arch Dermatol. 2006;142(7):934.
EXTRACT
| FULL TEXT
Topical Tacrolimus for Effective Treatment of Eosinophilic Folliculitis Associated With Human Immunodeficiency Virus Infection
Laurence Toutous-Trellu, Shahnaz Abraham, Marc Pechère, Pierre Chavaz, Jan Lübbe, Véronique Schiffer, Bernard Hirschel, Jean-Hilaire Saurat, and Vincent Piguet
Arch Dermatol. 2005;141(10):1203-1208.
EXTRACT
| FULL TEXT
|
